BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081-1088. [PMID: 19577010 DOI: 10.1016/j.cgh.2009.06.024] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
2 Lamers CR, van Erp LW, Slotegraaf AI, Groenen MJM, de Roos NM, Wahab PJ, Witteman BJM. Web-based dietary assessment and advice helps inflammatory bowel disease patients to improve their diet quality. Br J Nutr 2022. [DOI: 10.1017/s0007114522001064] [Reference Citation Analysis]
3 Su S, Marrie RA, Bernstein CN. Factors Associated With Social Participation in Persons Living With Inflammatory Bowel Disease. J Can Assoc Gastroenterol 2022;5:59-67. [PMID: 35368323 DOI: 10.1093/jcag/gwab022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lacombe LAC, Matiollo C, Rosa JSD, Felisberto M, Dalmarco EM, Schiavon LL. FACTORS ASSOCIATED WITH CIRCULATING ZONULIN IN INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2022;59:238-43. [PMID: 35830035 DOI: 10.1590/S0004-2803.202202000-43] [Reference Citation Analysis]
5 Gomollón F, Seoane-Mato D, Montoro MA, Juanola X, Trujillo-Martin E, Carrillo-Palau M, Matallana V, García-Magallón B, Ber Y, Ramos L, Perez-Pampin E, Ferreiro-Iglesias R, Rodríguez-Alonso L, Marco-Pascual C, Sanz Sanz J; Validación-PIIASER Study Group. Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice. Dig Liver Dis 2022:S1590-8658(21)00897-5. [PMID: 35039222 DOI: 10.1016/j.dld.2021.12.010] [Reference Citation Analysis]
6 Xian J, Zhong X, Gu H, Wang X, Li J, Li J, Wu Y, Zhang C, Zhang J. Colonic Delivery of Celastrol-Loaded Layer-by-Layer Liposomes with Pectin/Trimethylated Chitosan Coating to Enhance Its Anti-Ulcerative Colitis Effects. Pharmaceutics 2021;13:2005. [PMID: 34959287 DOI: 10.3390/pharmaceutics13122005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
7 Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis 2021:S1590-8658(21)00761-1. [PMID: 34538764 DOI: 10.1016/j.dld.2021.08.020] [Reference Citation Analysis]
8 van Erp LW, Groenen MJM, Heida W, Wisse J, Roosenboom B, Wahab PJ. Mobile application to monitor inflammatory bowel disease patients on intravenous biologic treatment: a feasibility study. Scand J Gastroenterol 2021;56:1414-21. [PMID: 34448665 DOI: 10.1080/00365521.2021.1966832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. J Crohns Colitis 2020;14:1190-201. [PMID: 32100016 DOI: 10.1093/ecco-jcc/jjaa035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
10 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
11 Atia O, Gupta A, Travis S, Turner D, Koslowsky B. The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis. Scand J Gastroenterol 2021;56:1049-55. [PMID: 34261387 DOI: 10.1080/00365521.2021.1947368] [Reference Citation Analysis]
12 Yang S, Park JS, Hwang SH, Cho KH, Na HS, Choi J, Jhun J, Kim SJ, Lee BI, Park SH, Cho ML. Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation. Front Immunol 2021;12:652709. [PMID: 34211461 DOI: 10.3389/fimmu.2021.652709] [Reference Citation Analysis]
13 van Erp LW, van Gerven J, Bloem S, Groenen MJM, Wahab PJ. Acceptance and perceived control are independently associated with quality of life in inflammatory bowel disease: Introduction of a new segmentation model. J Crohns Colitis 2021:jjab082. [PMID: 33909079 DOI: 10.1093/ecco-jcc/jjab082] [Reference Citation Analysis]
14 Shaoul R, Day AS. An Overview of Tools to Score Severity in Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:615216. [PMID: 33912519 DOI: 10.3389/fped.2021.615216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 2021;44:312-319. [DOI: 10.1016/j.gastre.2020.06.023] [Reference Citation Analysis]
16 Walsh A, Cao R, Wong D, Kantschuster R, Matini L, Wilson J, Kormilitzin A, South M, Travis S, Bauermeister S. Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. BMC Gastroenterol 2021;21:132. [PMID: 33752610 DOI: 10.1186/s12876-021-01621-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
18 Scolaro BL, Barretta C, Matos CH, Malluta EF, Almeida IBTD, Braggio LD, Bobato S, Specht CM. Deficiency of vitamin D and its relation with clinical and laboratory activity of inflammatory bowel diseases. Journal of Coloproctology 2021;38:099-104. [DOI: 10.1016/j.jcol.2017.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
19 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 349] [Cited by in F6Publishing: 382] [Article Influence: 349.0] [Reference Citation Analysis]
20 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 D'Arcangelo G, Aloi M. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? Paediatr Drugs 2020;22:463-72. [PMID: 32572841 DOI: 10.1007/s40272-020-00406-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
23 Banerjee R, Pal P, Penmetsa A, Kathi P, Girish G, Goren I, Reddy DN. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study. J Clin Gastroenterol 2021;55:702-8. [PMID: 32889959 DOI: 10.1097/MCG.0000000000001416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
24 Scarallo L, Maniscalco V, Paci M, Renzo S, Naldini S, Barp J, Tasciotti L, Lionetti P. Bowel Ultrasound Scan Predicts Corticosteroid Failure in Children With Acute Severe Colitis. Journal of Pediatric Gastroenterology & Nutrition 2020;71:46-51. [DOI: 10.1097/mpg.0000000000002677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Breidert M, Eftekhari P, Louis F, Rotoiu C, Rath T, Neurath MF, Atreya R. Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients. Crohns Colitis 360 2020;2:otaa037. [PMID: 32776006 DOI: 10.1093/crocol/otaa037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Kul Ş, Çalışkan Z, Güvenç TS, Güvenç RÇ, Çalışkan M. Plasma lipids in patients with inflammatory bowel disease : Observations on the associations between lipid indices and coronary flow reserve. Wien Klin Wochenschr 2020;132:283-94. [PMID: 32347376 DOI: 10.1007/s00508-020-01649-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastro 2020;18:15-32. [DOI: 10.1007/s11938-019-00259-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Lair-mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-biroulet L, Simon M, Viennot S, Bouhnik Y. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease 2020;52:268-73. [DOI: 10.1016/j.dld.2019.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
29 Rogler G, Biedermann L. Klassifikationen, Indizes, Aktivitätsbeurteilung. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_8] [Reference Citation Analysis]
30 Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut 2020;69:32-41. [PMID: 30979718 DOI: 10.1136/gutjnl-2018-317987] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
31 Keller K. Medikamentöse Therapie der CED bei Kindern und Jugendlichen. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_28] [Reference Citation Analysis]
32 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 572] [Cited by in F6Publishing: 603] [Article Influence: 190.7] [Reference Citation Analysis]
33 Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. Clin Pharmacol Ther 2020;107:1189-99. [PMID: 31677154 DOI: 10.1002/cpt.1712] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
34 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 149] [Cited by in F6Publishing: 163] [Article Influence: 49.7] [Reference Citation Analysis]
35 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 174] [Cited by in F6Publishing: 190] [Article Influence: 58.0] [Reference Citation Analysis]
36 Tajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. BMC Pediatr 2019;19:351. [PMID: 31607268 DOI: 10.1186/s12887-019-1739-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Borren NZ, Tan W, Colizzo FP, Luther J, Garber JJ, Khalili H, van Der Woude CJ, Ananthakrishnan AN. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. Journal of Crohn's and Colitis 2020;14:309-15. [DOI: 10.1093/ecco-jcc/jjz148] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
38 Gou S, Huang Y, Wan Y, Ma Y, Zhou X, Tong X, Huang J, Kang Y, Pan G, Dai F, Xiao B. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials 2019;212:39-54. [DOI: 10.1016/j.biomaterials.2019.05.012] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 36.0] [Reference Citation Analysis]
39 Slonim-Nevo V, Sarid O, Friger M, Schwartz D, Sergienko R, Pereg A, Vardi H, Singer T, Chernin E, Greenberg D, Odes S; Israeli IBD Research Nucleus (IIRN). Effect of Social Support on Psychological Distress and Disease Activity in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2018;24:1389-400. [PMID: 29893949 DOI: 10.1093/ibd/izy041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
40 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. Revista de Gastroenterología de México (English Edition) 2019;84:317-25. [DOI: 10.1016/j.rgmxen.2019.02.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validación de un nuevo índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. Revista de Gastroenterología de México 2019;84:317-25. [DOI: 10.1016/j.rgmx.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist C, Posfay-barbe KM; the Swiss Inflammatory Bowel Disease Cohort Study Group. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol 2019;114:1130-41. [DOI: 10.14309/ajg.0000000000000289] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
43 Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA. Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflamm Bowel Dis 2018;24:997-1004. [PMID: 29668901 DOI: 10.1093/ibd/izx110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
44 Turner D. Particularities of IBD Trials in Children. CPD 2019;25:69-72. [DOI: 10.2174/1381612825666190307125511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
46 Deva Rajoo G, Tan L, Lopez A, Lewindon P, Grover Z. Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis. Dig Dis Sci 2019;64:1929-37. [DOI: 10.1007/s10620-019-05486-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
47 Zhang L, Wu T. Inflammatory Bowel Disease. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases 2019. [DOI: 10.1007/978-3-030-15573-5_15] [Reference Citation Analysis]
48 Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
49 Shin DS, Cheon JH, Park YE, Park Y, Park SJ, Kim TI, Kim WH. Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis. Dig Dis Sci 2018;63:3097-104. [DOI: 10.1007/s10620-018-5218-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Ricciuto A, Fish J, Carman N, Walters TD, Church PC, Hansen BE, Crowley E, Siddiqui I, Nguyen GC, Kamath BM, Griffiths AM. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2018;16:1098-1105.e1. [PMID: 29378308 DOI: 10.1016/j.cgh.2018.01.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
51 Geisz M, Ha C, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS, Long MD. Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1435-41. [PMID: 26978725 DOI: 10.1097/MIB.0000000000000747] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
52 Gubatan J, Mitsuhashi S, Longhi MS, Zenlea T, Rosenberg L, Robson S, Moss AC. Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. Cytokine. 2018;103:38-45. [PMID: 29324259 DOI: 10.1016/j.cyto.2017.12.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
53 Panés J, Domènech E, Aguas Peris M, Nos P, Riestra S, Juliá de Páramo B, Cea-calvo L, Romero C, Marín-jiménez I. Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study: Disease activity and QoL in ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:1818-24. [DOI: 10.1111/jgh.13795] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
54 Valer P, Algaba A, Santos D, Fuentes ME, Nieto E, Gisbert JP, López P, Quintanilla E, García-alonso FJ, Guerra I, Páez Á, Bermejo F. Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1144-53. [DOI: 10.1097/mib.0000000000001081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
55 Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, Rufo PA, Bousvaros A. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol 2017; 23(18): 3322-3329 [PMID: 28566893 DOI: 10.3748/wjg.v23.i18.3322] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
56 Hvas CL, Dige A, Bendix M, Wernlund PG, Christensen LA, Dahlerup JF, Agnholt J. Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. Eur J Clin Invest 2016;46:555-63. [PMID: 27090817 DOI: 10.1111/eci.12634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
57 Slonim-nevo V, Sarid O, Friger M, Schwartz D, Sergienko R, Pereg A, Vardi H, Singer T, Chernin E, Greenberg D, Odes S. Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn’s disease. European Journal of Gastroenterology & Hepatology 2017;29:577-86. [DOI: 10.1097/meg.0000000000000826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
58 Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J; The SWIBREG Vedolizumab Study Group. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology 2017;52:722-9. [DOI: 10.1080/00365521.2017.1304987] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 16.8] [Reference Citation Analysis]
59 Marcovitch L, Nissan A, Mack D, Otley A, Hussey S, Mclean B, Lewis M, Croft N, Barakat FM, Griffiths AM, Turner D. Item Generation and Reduction Toward Developing a Patient-reported Outcome for Pediatric Ulcerative Colitis (TUMMY-UC). Journal of Pediatric Gastroenterology & Nutrition 2017;64:373-7. [DOI: 10.1097/mpg.0000000000001259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
60 Sexton KA, Walker JR, Graff LA, Bernstein MT, Beatie B, Miller N, Sargent M, Targownik LE. Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017;23:473-83. [DOI: 10.1097/mib.0000000000001040] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
61 Manolakis AC, Christodoulidis G, Kapsoritakis AN, Georgoulias P, Tiaka EK, Oikonomou K, Valotassiou VJ, Potamianos SP. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 437-446 [PMID: 28210079 DOI: 10.3748/wjg.v23.i3.437] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
62 Turner D, Ledder O. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_46] [Reference Citation Analysis]
63 deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, Kaplan GG, Seow CH, Wrobel I. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis 2016;22:638-47. [PMID: 26595551 DOI: 10.1097/MIB.0000000000000615] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
64 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
65 Aggio RBM, White P, Jayasena H, de Lacy Costello B, Ratcliffe NM, Probert CSJ. Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis. Aliment Pharmacol Ther 2017;45:82-90. [DOI: 10.1111/apt.13822] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
66 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 121] [Cited by in F6Publishing: 130] [Article Influence: 20.2] [Reference Citation Analysis]
67 Alrubaiy L, Rikaby I, Sageer M, Hutchings HA, Williams JG. Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2460-6. [PMID: 25966838 DOI: 10.1097/MIB.0000000000000438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
68 Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2017; 15: 240-246. e1. [PMID: 27266980 DOI: 10.1016/j.cgh.2016.05.035] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 10.7] [Reference Citation Analysis]
69 Marín-jiménez I, Panés J. Response to Gracie and Ford. American Journal of Gastroenterology 2016;111:901-902. [DOI: 10.1038/ajg.2016.147] [Reference Citation Analysis]
70 Cherfane CE, Gessel L, Cirillo D, Zimmerman MB, Polyak S. Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflamm Bowel Dis. 2015;21:1769-1775. [PMID: 25993688 DOI: 10.1097/mib.0000000000000427] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
71 Kolho K. Assessment of disease activity in pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2016;10:1127-34. [DOI: 10.1080/17474124.2016.1185364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
72 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016;65:408-14. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 227] [Cited by in F6Publishing: 261] [Article Influence: 37.8] [Reference Citation Analysis]
73 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 228] [Cited by in F6Publishing: 236] [Article Influence: 38.0] [Reference Citation Analysis]
74 Jones PD, Kappelman MD, Martin CF, Chen W, Sandler RS, Long MD. Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis. 2015;21:1063-1071. [PMID: 25723616 DOI: 10.1097/mib.0000000000000333] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 7.8] [Reference Citation Analysis]
75 Marín-jiménez I, Nos P, Domènech E, Riestra S, Gisbert JP, Calvet X, Cortés X, Iglesias E, Huguet JM, Taxonera C, Fernández R, Carpio D, Gutiérrez A, Guardiola J, Laria LC, Sicilia B, Bujanda L, Cea-calvo L, Romero C, Rincón Ó, Juliá B, Panés J. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. American Journal of Gastroenterology 2016;111:261-8. [DOI: 10.1038/ajg.2015.403] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
76 Kim DB, Lee KM, Lee JM, Chung YY, Sung HJ, Paik CN, Chung WC, Jung JH, Choi HJ. Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis. Gastroenterol Res Pract 2016;2016:5832051. [PMID: 26839541 DOI: 10.1155/2016/5832051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
77 Castro FDD, Magalhães J, Carvalho PB, Moreira MJ, Mota P, Cotter J. LOWER LEVELS OF VITAMIN D CORRELATE WITH CLINICAL DISEASE ACTIVITY AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2015;52:260-5. [DOI: 10.1590/s0004-28032015000400003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
78 Pan WJ, Köck K, Rees WA, Sullivan BA, Evangelista CM, Yen M, Andrews JM, Radford-Smith GL, Prince PJ, Reynhardt KO. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol. 2014;78:1315-1333. [PMID: 24803302 DOI: 10.1111/bcp.12418] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
79 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 1139] [Cited by in F6Publishing: 1169] [Article Influence: 162.7] [Reference Citation Analysis]
80 Sun H, Vesely R, Taminiau J, Szitanyi P, Papadopoulos EJ, Isaac M, Klein A, Uzu S, Griebel D, Mulberg AE; International Inflammatory Bowel Disease Working Group. Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 1: efficacy endpoints and disease outcome assessments. J Pediatr Gastroenterol Nutr 2014;58:679-83. [PMID: 24866781 DOI: 10.1097/MPG.0000000000000306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
81 Targownik LE, Sexton KA, Bernstein MT, Beatie B, Sargent M, Walker JR, Graff LA. The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am J Gastroenterol. 2015;110:1001-12; quiz 1013. [PMID: 26077178 DOI: 10.1038/ajg.2015.147] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 14.6] [Reference Citation Analysis]
82 Schechter A, Griffiths C, Gana JC, Shaoul R, Shamir R, Shteyer E, Bdolah-Abram T, Ledder O, Turner D. Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut 2015;64:580-8. [PMID: 24848266 DOI: 10.1136/gutjnl-2014-306999] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
83 Ruemmele FM, Hyams JS, Otley A, Griffiths A, Kolho KL, Dias JA, Levine A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner D. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2015;64:438-46. [PMID: 24821616 DOI: 10.1136/gutjnl-2014-307008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
84 Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015;13:1444-9.e1. [PMID: 25724700 DOI: 10.1016/j.cgh.2015.02.019] [Cited by in Crossref: 199] [Cited by in F6Publishing: 263] [Article Influence: 28.4] [Reference Citation Analysis]
85 Hosseini SV, Jafari P, Taghavi SA, Safarpour AR, Rezaianzadeh A, Moini M, Mehrabi M. Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J 2015;17:e22796. [PMID: 25793117 DOI: 10.5812/ircmj.22796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
86 Bewtra M, Brensinger CM, Tomov VT, Hoang TB, Sokach CE, Siegel CA, Lewis JD. An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis. 2014;20:1070-1078. [PMID: 24810138 DOI: 10.1097/mib.0000000000000053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
87 Kolho KL, Sipponen T, Valtonen E, Savilahti E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43-50. [PMID: 24077667 DOI: 10.1007/s00384-013-1775-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
88 Sun H, Lee JJ, Papadopoulos EJ, Lee CS, Nelson RM, Sachs HC, Rodriguez WJ, Mulberg AE. Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. J Pediatr Gastroenterol Nutr. 2014;58:12-17. [PMID: 24121142 DOI: 10.1097/mpg.0000000000000186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
89 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
90 Turner D, Levine A, Kolho KL, Shaoul R, Ledder O. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report. J Crohns Colitis. 2014;8:1464-1470. [PMID: 24958064 DOI: 10.1016/j.crohns.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 8.1] [Reference Citation Analysis]
91 Gray FL, Turner CG, Zurakowski D, Bousvaros A, Linden BC, Shamberger RC, Lillehei CW. Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis. J Pediatr Surg. 2013;48:1540-1545. [PMID: 23895969 DOI: 10.1016/j.jpedsurg.2013.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
92 Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Mäkitie O. Compromised peak bone mass in patients with inflammatory bowel disease--a prospective study. J Pediatr 2014;164:1436-43.e1. [PMID: 24650398 DOI: 10.1016/j.jpeds.2014.01.073] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
93 Randell RL, Long MD, Martin CF, Sandler RS, Chen W, Anton K, Kappelman MD. Patient perception of chronic illness care in a large inflammatory bowel disease cohort. Inflamm Bowel Dis 2013;19:1428-33. [PMID: 23574758 DOI: 10.1097/MIB.0b013e3182813434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
94 Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:597-601. [PMID: 23542823 DOI: 10.1097/mpg.0b013e318292fa0d] [Cited by in Crossref: 210] [Cited by in F6Publishing: 235] [Article Influence: 26.3] [Reference Citation Analysis]
95 Navas-lópez V, Blasco Alonso J, Serrano Nieto M, Girón Fernández-crehuet F, Argos Rodriguez M, Sierra Salinas C. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. Journal of Crohn's and Colitis 2014;8:64-9. [DOI: 10.1016/j.crohns.2013.03.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
96 Palmer R, Walsh A, Travis S. Assessment of Disease Activity in Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_32] [Reference Citation Analysis]
97 Kim B, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49:177-183. [PMID: 24325564 DOI: 10.3109/00365521.2013.867360] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
98 Papathanasopoulos A, Van Oudenhove L, Katsanos K, Christodoulou D, Tack J, Tsianos EV. Severity of Fecal Urgency and Incontinence in Inflammatory Bowel Disease: Clinical, Manometric and Sonographic Predictors. Inflammatory Bowel Diseases 2013;19:2450-6. [DOI: 10.1097/mib.0b013e3182a2952b] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
99 Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779-784. [PMID: 23446338 DOI: 10.1097/mib.0b013e3182802b0e] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 6.4] [Reference Citation Analysis]
100 Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341. [PMID: 23328771 DOI: 10.1097/mib.0b013e3182810066] [Cited by in Crossref: 187] [Cited by in F6Publishing: 202] [Article Influence: 20.8] [Reference Citation Analysis]
101 Gomollón F, García-lópez S, Sicilia B, Gisbert JP, Hinojosa J. The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. Gastroenterología y Hepatología 2013;36:483.e1-483.e46. [DOI: 10.1016/j.gastrohep.2012.11.002] [Reference Citation Analysis]
102 Turner D, Griffiths AM, Veerman G, Johanns J, Damaraju L, Blank M, Hyams J. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:1460-1465. [PMID: 23672831 DOI: 10.1016/j.cgh.2013.04.049] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
103 Kolho KL, Turner D. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol 2013;2013:179024. [PMID: 23533791 DOI: 10.1155/2013/179024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
104 Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM; European Crohn's and Colitis Organization; European Society for Paediatric Gastroenterology; Hepatology; and Nutrition. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55:340-361. [PMID: 22773060 DOI: 10.1097/mpg.0b013e3182662233] [Cited by in Crossref: 272] [Cited by in F6Publishing: 287] [Article Influence: 30.2] [Reference Citation Analysis]
105 Zeisler B, Lerer T, Markowitz J, Mack D, Griffiths A, Bousvaros A, Keljo D, Rosh J, Evans J, Kappelman M, Otley A, Kay M, Grossman A, Saeed S, Carvalho R, Oliva-hemker M, Faubion W, Sudel B, Pfefferkorn M, Ashai-khan F, Leleiko N, Hyams J. Outcome Following Aminosalicylate Therapy in Children Newly Diagnosed As Having Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2013;56:12-8. [DOI: 10.1097/mpg.0b013e31826ac41a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
106 Noble A, Turner D. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-5061-0_41] [Reference Citation Analysis]
107 Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, Wahbeh GT, Sena LM, Faubion WA. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012;55:93-108. [PMID: 22516861 DOI: 10.1097/mpg.0b013e31825959b8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 8.0] [Reference Citation Analysis]
108 Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?: . Inflammatory Bowel Diseases 2012;18:2056-62. [DOI: 10.1002/ibd.22879] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
109 Long MD, Kappelman MD, Martin CF, Lewis JD, Mayer L, Kinneer PM, Sandler RS. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): Methodology and initial results: . Inflammatory Bowel Diseases 2012;18:2099-106. [DOI: 10.1002/ibd.22895] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 8.6] [Reference Citation Analysis]
110 Lee JJ, Colman RJ, Mitchell PD, Atmadja ML, Bousvaros A, Lightdale JR. Agreement between patient- and physician-completed Pediatric Ulcerative Colitis Activity Index scores. J Pediatr Gastroenterol Nutr. 2011;52:708-713. [PMID: 21593644 DOI: 10.1097/mpg.0b013e3182099018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
111 Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18:1470-1479. [PMID: 22147460 DOI: 10.1002/ibd.21896] [Cited by in Crossref: 159] [Cited by in F6Publishing: 172] [Article Influence: 14.5] [Reference Citation Analysis]
112 Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011;17:440-9. [PMID: 20645317 DOI: 10.1002/ibd.21383] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 6.5] [Reference Citation Analysis]
113 Manolakis AC, Kapsoritakis AN, Georgoulias P, Tzavara C, Valotassiou V, Kapsoritaki A, Potamianos SP. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118. [PMID: 20946669 DOI: 10.1186/1471-230x-10-118] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
114 Benharush D, Cohen MJ, Kasirer Y, Turner D. Short chain fatty acids (butyrate) for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008730] [Reference Citation Analysis]
115 Kabakchiev B, Turner D, Hyams J, Mack D, Leleiko N, Crandall W, Markowitz J, Otley AR, Xu W, Hu P, Griffiths AM, Silverberg MS. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010;5:e13085. [PMID: 20941359 DOI: 10.1371/journal.pone.0013085] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
116 Van Limbergen J, Griffiths AM. Pediatric Inflammatory Bowel Disease in the Emergency Department. Clinical Pediatric Emergency Medicine 2010;11:189-197. [DOI: 10.1016/j.cpem.2010.06.004] [Reference Citation Analysis]
117 Aloi M, Di Nardo G, Conte F, Mazzeo L, Cavallari N, Nuti F, Cucchiara S, Stronati L. Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre: Methotrexate in paediatric ulcerative colitis. Alimentary Pharmacology & Therapeutics 2010;32:1017-22. [DOI: 10.1111/j.1365-2036.2010.04433.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
118 Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3168-3177 [PMID: 20593502 DOI: 10.3748/wjg.v16.i25.3168] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 99] [Article Influence: 7.9] [Reference Citation Analysis]
119 Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS, Crandall W, Silverberg MS, Markowitz J. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282-2291. [PMID: 20193683 DOI: 10.1053/j.gastro.2010.02.047] [Cited by in Crossref: 178] [Cited by in F6Publishing: 190] [Article Influence: 14.8] [Reference Citation Analysis]
120 Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286-1296, 1286-1296. [PMID: 20064514 DOI: 10.1053/j.gastro.2009.12.054] [Cited by in Crossref: 89] [Cited by in F6Publishing: 100] [Article Influence: 7.4] [Reference Citation Analysis]
121 La Montagna G, Parenti M, Oliani C, Filippi F, Tirri G. [Beta-cyclodextrin-piroxicam in the treatment of the active phase of osteoarthritic pathology]. Riv Eur Sci Med Farmacol. 1990;12:265-272. [PMID: 2103967 DOI: 10.1111/j.1365-2036.2010.04459.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 0.7] [Reference Citation Analysis]